|
Making digi-trials a reality for cancer
Making digi-trials a reality for cancer
|
Simon Leedham,
Brian Nicholson,
Eva Morris
|
|
Using online platforms to empower patient driven research
Using online platforms to empower patient driven research
|
Mark Middleton
|
|
New statistical tools for the topological data analysis of tumour tissue
New statistical tools for the topological data analysis of tumour tissue
|
Helen Byrne,
Heather Harrington,
Chris Pugh,
Ulrike Tillmann
|
|
In silico simulation of the tumour-host interaction
In silico simulation of the tumour-host interaction
|
Francesca Buffa,
Tim Elliott,
Mark Coles,
Hashem Koohy,
Eamonn Gaffney,
Philip Maini
|
|
Applying morpho-molecular pathology
Applying morpho-molecular pathology
|
Simon Leedham,
Jens Rittscher,
Clare Verrill,
Daniel Royston
|
|
Assessing risk of cancer using GP patient records
Assessing risk of cancer using GP patient records
|
Brian Nicholson,
Karthik Ramasamy,
Constantinos Koshiaris,
Kassim Javaid
|
|
Factors determining ovarian cancer risk
Factors determining ovarian cancer risk
|
Ahmed Ahmed,
Hagan Bayley,
Sarah Blagden
|
|
Early intervention trials
Early intervention trials
|
Sarah Blagden,
Simon Leedham,
Xin Lu
|
|
Remodelling the tissue immune microenvironment (TIME) during tumour development
Remodelling the tissue immune microenvironment (TIME) during tumour development
|
Simon Leedham,
Simon Buczacki,
Kim Midwood,
Audrey Gérard
|
|
Optimising TIME for radiotherapy response
Optimising TIME for radiotherapy response
|
Richard Bryant,
Eileen Parkes,
Ian Mills
|
|
Comprehensive characterisation of shared immune mechanisms in organ-specific checkpoint induced and spontaneous autoinflammation
Comprehensive characterisation of shared immune mechanisms in organ-specific checkpoint induced and spontaneous autoinflammation
|
Ben Fairfax,
Fiona Powrie,
Holm Uhlig,
Simon Leedham
|
|
Determining the molecular basis for the relationship between IT efficacy and toxicity
Determining the molecular basis for the relationship between IT efficacy and toxicity
|
Ben Fairfax,
Mark Middleton,
Benoît Van den Eynde,
Adrian Hill,
Paresh Vyas,
Ronjon Chakreverty
|
|
Reducing systemic dose whilst enhancing efficacy
Reducing systemic dose whilst enhancing efficacy
|
Robert Carlisle,
Constantin Coussios,
David Kerr
|
|
Identification of cancer epitope targets
Identification of cancer epitope targets
|
Tim Elliott,
David Church,
Andrew McMichael,
Ricardo Fernandes,
Nicola Ternette,
Hashem Koohy,
Michael Dustin,
Paresh Vyas,
Ahmed Ahmed
|
|
Determination of the relative importance of T-cell intrinsic and extrinsic factors in immune escape
Determination of the relative importance of T-cell intrinsic and extrinsic factors in immune escape
|
Oliver Brain,
David Church,
Ben Fairfax,
Paul Klenerman,
Fiona Powrie
|
|
Activation of tumour infiltrating B cells
Activation of tumour infiltrating B cells
|
Rachael Bashford-Rogers,
Shivan Sivakumar,
Persephone Borrow
|
|
Understanding prostate cancer progression
Understanding prostate cancer progression
|
Clare Verrill,
Jens Rittscher,
Ian Mills,
Victoria Woodcock,
Richard Bryant,
Alastair Lamb,
Freddie Hamdy
|
|
Development of multi-cancer tests and studying early cancer biology
Development of multi-cancer tests and studying early cancer biology
|
Daniel Anthony,
Brian Nicholson,
Anna Schuh,
Nicola Sibson
|
|
Choosing the right diagnostic test to improve the patient experience
Choosing the right diagnostic test to improve the patient experience
|
Fergus Gleeson,
Julia Hippisley-Cox,
Richard Hobbs,
David Hunter,
Gillian Reeves
|
|
Polygenic risk scores
Polygenic risk scores
|
Freddie Hamdy,
Jenny Taylor,
David Hunter
|
|
Optimising cancer detection and diagnosis in primary care
Optimising cancer detection and diagnosis in primary care
|
Julia Hippisley-Cox
|
|
The Million Women Study
The Million Women Study
|
Gillian Reeves
|
|
Application of topological data analysis to clinical trials
Application of topological data analysis to clinical trials
|
Xin Lu,
Helen Byrne,
Heather Harrington
|
|
Developing intelligent image-based predictors of GI & lung cancer risk
Developing intelligent image-based predictors of GI & lung cancer risk
|
Barbara Braden,
James East,
Fergus Gleeson,
Nick Maynard,
Alison Noble,
Jens Rittscher
|
|
Integrating molecular diagnostics to predict progression from monoclonal gammopathy of undetermined significance (MGUS) to myeloma and intercept & treat individuals at highest risk
Integrating molecular diagnostics to predict progression from monoclonal gammopathy of undetermined significance (MGUS) to myeloma and intercept & treat individuals at highest risk
|
Udo Oppermann,
Karthik Ramasamy,
Anna Schuh,
Chris Schofield
|
|
Universal consent at the Oxford University Hospitals (OUH) Translational Gastroenterology Unit
Universal consent at the Oxford University Hospitals (OUH) Translational Gastroenterology Unit
|
Simon Leedham,
Xin Lu,
Jens Rittscher
|